Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

Methodist Health System

Status: Completed

Conditions: Unfractionated Heparin

Study type: Observational

Funder types: Other

Identifiers

NCT06096064

100.PHA.2022.R

Details and patient eligibility

About

Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels

Full description

Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate anticoagulation can lead to life threatening events such as a major bleed or thrombus formation and/or death.

Enrollment: 100 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy

Exclusion criteria

• History of bleeding in the last 30 days
• History of HIT
• Use of systemic anticoagulants for another indication
• Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)